Search Results
Results found for "Ralf Jockers"
Posts (19)
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
in dense receptor environments amplifies target occupancy, even post-clearance ✅ Insight into why half-life Why Half-Life Can Lie to You Most teams use systemic half-life as a proxy for action.
- Radioligands vs. Fluorescent Ligands: Binding Assays
The problem is their long half-life, which results in lower detection efficiency. Another common radioactive atom, 125I, with a higher specific activity, but a shorter half-life (60 days
Other Pages (4)
- Dr. Ralf Jockers | Dr. GPCR Ecosystem
Ralf Jockers About Dr. Ralf Jockers Ralf Jockers studied in Cologne and received a Ph.D. in biotechnology and biochemistry from Ralf Jockers on the web Jockers Lab WGDR-3545 Pubmed Dr. GPCR Ecosystem Enjoying the Dr.
- Session V | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Authors & Affiliations "Fabian Pohl1, Florian Seufert2, Yin Kwan Chung3, Daniela Volke1, Ralf Hoffmann1
- GPCRs and the Science Behind Pain and Recovery with Dr. Alex Serafini | Dr. GPCR Ecosystem
“Half the time, in pain, what works in vivo doesn’t translate to clinic.
